Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review

Jianyi Zhang; Roberto Bolli; Daniel J. Garry; Eduardo Marbán; Philippe Menasché; Wolfram Hubertus Zimmermann; Timothy J. Kamp; Joseph C. Wu; Victor J. Dzau

doi:10.1016/j.jacc.2021.09.019

Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review

Jianyi Zhang, Roberto Bolli, Daniel J. Garry, Eduardo Marbán, Philippe Menasché, Wolfram Hubertus Zimmermann, Timothy J. Kamp, Joseph C. Wu, Victor J. Dzau

Medicine - Cardiology Division

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors’ own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.

Original language	English (US)
Pages (from-to)	2092-2105
Number of pages	14
Journal	Journal of the American College of Cardiology
Volume	78
Issue number	21
DOIs	https://doi.org/10.1016/j.jacc.2021.09.019
State	Published - Nov 23 2021

Bibliographical note

Funding Information:
This work was supported in part by the NIH UO1 HL134764. Dr Garry is the cofounder of NorthStar Genomics with no compensation. Dr Marbán has significant equity in Capricor Inc. Dr Zimmermann is founder and advisor of Repairon GmbH with no compensation. Dr Kamp has received modest compensation as a consultant for FujifilmCDI. Dr Wu is cofounder and advisor of Khloris Biosciences. Dr Dzau served on the Medtronic board until 2014, and received deferred compensation until 2018. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding Information:
The authors thank the National Institutes of Health for their support of the Progenitor Cell Translational Consortium; and are grateful for the Zoom discussions of the Cardiovascular Bioengineering Symposium held on December 5, 2020, which has resulted in this proceeding. The authors also thank Dr Conrad Hodgkinson, who worked on the original paper on direct reprograming.

Publisher Copyright:
© 2021 The Authors

Keywords

heart
heart failure
myocardial infarction
myocyte proliferation
pluripotent stem cell

Publisher link

10.1016/j.jacc.2021.09.019

Find It

Find It at U of M Libraries

Cite this

@article{0b34f1aa38304b4c988b8f62a98fcf74,

title = "Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review",

abstract = "This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors{\textquoteright} own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.",

keywords = "heart, heart failure, myocardial infarction, myocyte proliferation, pluripotent stem cell",

author = "Jianyi Zhang and Roberto Bolli and Garry, {Daniel J.} and Eduardo Marb{\'a}n and Philippe Menasch{\'e} and Zimmermann, {Wolfram Hubertus} and Kamp, {Timothy J.} and Wu, {Joseph C.} and Dzau, {Victor J.}",

note = "Funding Information: This work was supported in part by the NIH UO1 HL134764. Dr Garry is the cofounder of NorthStar Genomics with no compensation. Dr Marb{\'a}n has significant equity in Capricor Inc. Dr Zimmermann is founder and advisor of Repairon GmbH with no compensation. Dr Kamp has received modest compensation as a consultant for FujifilmCDI. Dr Wu is cofounder and advisor of Khloris Biosciences. Dr Dzau served on the Medtronic board until 2014, and received deferred compensation until 2018. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors thank the National Institutes of Health for their support of the Progenitor Cell Translational Consortium; and are grateful for the Zoom discussions of the Cardiovascular Bioengineering Symposium held on December 5, 2020, which has resulted in this proceeding. The authors also thank Dr Conrad Hodgkinson, who worked on the original paper on direct reprograming. Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = nov,

day = "23",

doi = "10.1016/j.jacc.2021.09.019",

language = "English (US)",

volume = "78",

pages = "2092--2105",

journal = "Journal of the American College of Cardiology.",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "21",

}

TY - JOUR

T1 - Basic and Translational Research in Cardiac Repair and Regeneration

T2 - JACC State-of-the-Art Review

AU - Zhang, Jianyi

AU - Bolli, Roberto

AU - Garry, Daniel J.

AU - Marbán, Eduardo

AU - Menasché, Philippe

AU - Zimmermann, Wolfram Hubertus

AU - Kamp, Timothy J.

AU - Wu, Joseph C.

AU - Dzau, Victor J.

N1 - Funding Information: This work was supported in part by the NIH UO1 HL134764. Dr Garry is the cofounder of NorthStar Genomics with no compensation. Dr Marbán has significant equity in Capricor Inc. Dr Zimmermann is founder and advisor of Repairon GmbH with no compensation. Dr Kamp has received modest compensation as a consultant for FujifilmCDI. Dr Wu is cofounder and advisor of Khloris Biosciences. Dr Dzau served on the Medtronic board until 2014, and received deferred compensation until 2018. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors thank the National Institutes of Health for their support of the Progenitor Cell Translational Consortium; and are grateful for the Zoom discussions of the Cardiovascular Bioengineering Symposium held on December 5, 2020, which has resulted in this proceeding. The authors also thank Dr Conrad Hodgkinson, who worked on the original paper on direct reprograming. Publisher Copyright: © 2021 The Authors

PY - 2021/11/23

Y1 - 2021/11/23

N2 - This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors’ own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.

AB - This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors’ own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.

KW - heart

KW - heart failure

KW - myocardial infarction

KW - myocyte proliferation

KW - pluripotent stem cell

UR - http://www.scopus.com/inward/record.url?scp=85118613899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118613899&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2021.09.019

DO - 10.1016/j.jacc.2021.09.019

M3 - Review article

C2 - 34794691

AN - SCOPUS:85118613899

SN - 0735-1097

VL - 78

SP - 2092

EP - 2105

JO - Journal of the American College of Cardiology.

JF - Journal of the American College of Cardiology.

IS - 21

ER -

Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this